{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:40:38Z","timestamp":1789576838616,"version":"build-2803163510"},"reference-count":117,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":312,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Care and Resuscitation"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.51893\/2022.4.r","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T02:02:57Z","timestamp":1670205777000},"page":"298-308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Midodrine use in critically ill patients: a narrative review"],"prefix":"10.1016","volume":"24","author":[{"given":"Rahul","family":"Costa-Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Udy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Warrillow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinaldo","family":"Bellomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.51893\/2022.4.R_bb0005","unstructured":"K. Wismayr. AT 241435; Eidem, US Patent 3,340,298 (1965, 1967 both to Chemie Linz Ag)."},{"key":"10.51893\/2022.4.R_bb0010","first-page":"2145","article-title":"Pharmacodynamic actions of midodrine, a new alpha-adrenergic stimulating agent, and its main metabolite, ST 1059","volume":"26","author":"Pittner","year":"1976","journal-title":"Arzneimittelforschung"},{"key":"10.51893\/2022.4.R_bb0015","first-page":"1745","article-title":"Effects of midodrine on blood flow in dog vascular beds","volume":"36","author":"Tsuchida","year":"1986","journal-title":"Arzneimittelforschung"},{"key":"10.51893\/2022.4.R_bb0020","first-page":"96","article-title":"Krivanek P Plasma level of the prodrug midodrine and its active metabolite in comparison with the alpha-mimetic action in dogs","volume":"238","author":"Kolassa","year":"1979","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.51893\/2022.4.R_bb0025","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF00568204","article-title":"Vasoconstrictor effect of midodrine, ST 1059, noradrenaline, etilefrine and dihydroergotamine on isolated human veins","volume":"16","author":"Thulesius","year":"1979","journal-title":"Eur J Clin Pharmacol"},{"key":"10.51893\/2022.4.R_bb0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0306-3623(83)90075-7","article-title":"Vasoconstrictor effects of midodrine, ST 1059, noradrenaline, etilefrine and norfenefrine on isolated dog femoral arteries and veins","volume":"14","author":"Pittner","year":"1983","journal-title":"Gen Pharmacol"},{"key":"10.51893\/2022.4.R_bb0035","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S0022-5347(17)58270-1","article-title":"Treatment of female stress incontinence with midodrine: preliminary report","volume":"118","author":"Jonas","year":"1977","journal-title":"J Urol"},{"key":"10.51893\/2022.4.R_bb0040","first-page":"163","article-title":"[The conservative treatment of stress incontinence in women with midodrine] [German]","volume":"93","author":"Riccabona","year":"1981","journal-title":"Wien Klin Wochenschr"},{"key":"10.51893\/2022.4.R_bb0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000473102","article-title":"The use of midodrin in the treatment of ejaculation disorders following retroperitoneal lymphadenectomy","volume":"5","author":"Jonas","year":"1979","journal-title":"Eur Urol"},{"key":"10.51893\/2022.4.R_bb0050","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000473504","article-title":"Partial ejaculatory incompetence: the therapeutic effect of midodrine, an orally active selective alpha-adrenoceptor agonist","volume":"8","author":"Riley","year":"1982","journal-title":"Eur Urol"},{"key":"10.51893\/2022.4.R_bb0055","first-page":"429","article-title":"A new agent in the management of idiopathic orthostatic hypotension and Shy\u2013Drager syndrome","volume":"56","author":"Schirger","year":"1981","journal-title":"Mayo Clin Proc"},{"key":"10.51893\/2022.4.R_bb0060","first-page":"109","article-title":"[Treatment of hypotension caused by psychopharmacological drugs] [German]","volume":"131","author":"Hebenstreit","year":"1981","journal-title":"Wien Med Wochenschr"},{"key":"10.51893\/2022.4.R_bb0065","first-page":"733","article-title":"[Diagnosis and therapy of hypotensive circulatory disorders in general practice. Experiences with Gutron using the Thulesius-diagram for diagnosis and supervision of therapy] [German]","volume":"97","author":"Sazovsky","year":"1979","journal-title":"Fortschr Med"},{"key":"10.51893\/2022.4.R_bb0070","first-page":"59","article-title":"[The use of midodrin in the treatment of the orthostatic syndrome] [German]","volume":"16","author":"Hammerer","year":"1981","journal-title":"Padiatr Padol"},{"key":"10.51893\/2022.4.R_bb0075","first-page":"429","article-title":"[Studies on the effect of the alpha-receptor stimulant, gutron, in the orthostatic syndrome] [German]","volume":"93","author":"Scholing","year":"1981","journal-title":"Wien Klin Wochenschr"},{"key":"10.51893\/2022.4.R_bb0080","first-page":"211","article-title":"[Infectious toxic hypotension \u2014 effect and dosage of midodrine] [German]","volume":"14","author":"Weippl","year":"1979","journal-title":"Padiatr Padol"},{"key":"10.51893\/2022.4.R_bb0085","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0002-9343(93)90230-M","article-title":"Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine","volume":"95","author":"Jankovic","year":"1993","journal-title":"Am J Med"},{"key":"10.51893\/2022.4.R_bb0090","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0002-9343(99)80246-0","article-title":"Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension","volume":"99","author":"Fouad-Tarazi","year":"1995","journal-title":"Am J Med"},{"key":"10.51893\/2022.4.R_bb0095","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jama.1997.03540370036033","article-title":"Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group","volume":"277","author":"Low","year":"1997","journal-title":"JAMA"},{"key":"10.51893\/2022.4.R_bb0100","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1212\/WNL.51.1.120","article-title":"A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension","volume":"51","author":"Wright","year":"1998","journal-title":"Neurology"},{"key":"10.51893\/2022.4.R_bb0105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/08860229609052795","article-title":"Midodrine hydrochloride in patients on hemodialysis with chronic hypotension","volume":"18","author":"Fang","year":"1996","journal-title":"Ren Fail"},{"key":"10.51893\/2022.4.R_bb0110","first-page":"261","article-title":"Midodrine treatment for patients with hemodialysis hypotension","volume":"45","author":"Flynn","year":"1996","journal-title":"Clin Nephrol"},{"key":"10.51893\/2022.4.R_bb0115","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000190288","article-title":"Midodrine for the treatment of intradialytic hypotension","volume":"77","author":"Lim","year":"1997","journal-title":"Nephron"},{"key":"10.51893\/2022.4.R_bb0120","first-page":"101","article-title":"Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up","volume":"50","author":"Cruz","year":"1998","journal-title":"Clin Nephrol"},{"key":"10.51893\/2022.4.R_bb0125","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/hep.510280407","article-title":"Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites","volume":"28","author":"Angeli","year":"1998","journal-title":"Hepatology"},{"key":"10.51893\/2022.4.R_bb0130","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.510290629","article-title":"Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide","volume":"29","author":"Angeli","year":"1999","journal-title":"Hepatology"},{"key":"10.51893\/2022.4.R_bb0135","first-page":"629","article-title":"Regulatory actions on the off-label use of prescription drugs: ongoing controversy and contradiction in 2009 and 2010","volume":"16","author":"Fairman","year":"2010","journal-title":"J Manag Care Pharm"},{"key":"10.51893\/2022.4.R_bb0140","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/MJT.0b013e3181f7e4ea","article-title":"The midodrine withdrawal","volume":"17","author":"Somberg","year":"2010","journal-title":"Am J Ther"},{"key":"10.51893\/2022.4.R_bb0145","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1001\/jama.2010.1695","article-title":"Accelerated approval and possible withdrawal of midodrine","volume":"304","author":"Dhruva","year":"2010","journal-title":"JAMA"},{"key":"10.51893\/2022.4.R_bb0150","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10286-016-0363-9","article-title":"Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study","volume":"26","author":"Smith","year":"2016","journal-title":"Clin Auton Res"},{"key":"10.51893\/2022.4.R_bb0155","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2165\/00003495-198938050-00004","article-title":"A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders","volume":"38","author":"McTavish","year":"1989","journal-title":"Drugs"},{"key":"10.51893\/2022.4.R_bb0160","first-page":"80","article-title":"Effects of alpha-adrenoceptor agonists on cardiac output and blood pressure in spinally anesthetized ganglion-blocked dogs","volume":"295","author":"Yamazaki","year":"1988","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.51893\/2022.4.R_bb0165","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.clinthera.2008.09.001","article-title":"Pharmacokinetic and pharmacodynamic effects of midodrine on blood pressure, the autonomic nervous system, and plasma natriuretic peptides: a prospective, randomized, single-blind, two-period, crossover, placebo-controlled study","volume":"30","author":"Lamarre-Cliche","year":"2008","journal-title":"Clin Ther"},{"key":"10.51893\/2022.4.R_bb0170","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/clpt.1986.101","article-title":"Pharmacodynamics of midodrine, an antihypotensive agent","volume":"39","author":"Zachariah","year":"1986","journal-title":"Clin Pharmacol Ther"},{"key":"10.51893\/2022.4.R_bb0175","first-page":"637","article-title":"Cardiovascular parameters and catecholamines in volunteers during passive orthostasis","volume":"42","author":"Dominiak","year":"1992","journal-title":"Influence of antihypotensive drugs. Arzneimittelforschung"},{"key":"10.51893\/2022.4.R_bb0180","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-1838(91)90043-3","article-title":"Long-acting alpha 1-adrenoceptive sympathomimetic agent suppresses sympathetic outflow to muscles in humans","volume":"36","author":"Iwase","year":"1991","journal-title":"J Auton Nerv Syst"},{"issue":"1","key":"10.51893\/2022.4.R_bb0185","first-page":"222","article-title":"Validation of a population-based method to assess drug-induced alterations in the QT interval: a self-controlled crossover study","volume":"22","author":"Iribarren","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.51893\/2022.4.R_bb0190","first-page":"164","article-title":"[Investigations of the effect of midodrine on carbohydrate and fat metabolism with particular reference to the diabetic metabolic state] [German]","volume":"89","author":"Br\u00e4ndle","year":"1977","journal-title":"Wien Klin Wochenschr"},{"key":"10.51893\/2022.4.R_bb0195","first-page":"113","article-title":"Midodrine, a new therapeutic agent: recent experience","volume":"12","author":"Puchmayer","year":"1993","journal-title":"Int Angiol"},{"key":"10.51893\/2022.4.R_bb0200","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0165-5728(92)90154-D","article-title":"Continuous in vivo treatment with catecholamines suppresses in vitro reactivity of rat peripheral blood T-lymphocytes via -mediated mechanisms","volume":"37","author":"Felsner","year":"1992","journal-title":"J Neuroimmunol"},{"key":"10.51893\/2022.4.R_bb0205","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1540-8159.2005.50026.x","article-title":"Pregnancy in postural orthostatic tachycardia syndrome","volume":"28","author":"Glatter","year":"2005","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.51893\/2022.4.R_bb0210","first-page":"144","article-title":"Midodrine in pregnancy: a case report and literature review","volume":"4","author":"Al-Ghamdi","year":"2015","journal-title":"Cardiol Pharmacol"},{"key":"10.51893\/2022.4.R_bb0215","first-page":"447","article-title":"[The bioavailability of midodrin and alpha-2,5-dimethoxyphenyl-beta-aminoethanol hydrochloride] [German]","volume":"37","author":"Grobecker","year":"1987","journal-title":"Arzneimittelforschung"},{"key":"10.51893\/2022.4.R_bb0220","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF03190595","article-title":"The in vitro metabolism of desglymidodrine, an active metabolite of prodrug midodrine by human liver microsomes","volume":"29","author":"Akimoto","year":"2004","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.51893\/2022.4.R_bb0225","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0272-6386(96)90142-0","article-title":"Midodrine efficacy and pharmacokinetics in a patient with recurrent intradialytic hypotension","volume":"28","author":"Blowey","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.51893\/2022.4.R_bb0230","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00228-005-0941-6","article-title":"Adverse drug reactions related to drugs used in orthostatic hypotension: a prospective and systematic pharmacovigilance study in France","volume":"61","author":"Pathak","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.51893\/2022.4.R_bb0235","first-page":"158","article-title":"Takotsubo cardiomyopathy after midodrine therapy","volume":"39","author":"Ramanath","year":"2012","journal-title":"Tex Heart Inst J"},{"key":"10.51893\/2022.4.R_bb0240","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.4065\/76.12.1275","article-title":"Caudate hemorrhage as a possible complication of midodrine-induced supine hypertension","volume":"76","author":"Sandroni","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.51893\/2022.4.R_bb0245","article-title":"Reversible cerebral vasoconstriction syndrome due to midodrine in a patient with autonomic dysreflexia","volume":"11","author":"Shankar Kikkeri","year":"2019","journal-title":"Cureus"},{"key":"10.51893\/2022.4.R_bb0250","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021533","article-title":"Case report: severe myoclonus associated with oral midodrine treatment for hypotension","volume":"99","author":"Ye","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.51893\/2022.4.R_bb0255","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1080\/08860220802249025","article-title":"Midodrine-induced vascular ischemia in a hemodialysis patient: a case report and literature review","volume":"30","author":"Rubinstein","year":"2008","journal-title":"Ren Fail"},{"key":"10.51893\/2022.4.R_bb0260","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s10286-004-0176-0","article-title":"Intestinal obstruction associated with oral midodrine","volume":"14","author":"Pathak","year":"2004","journal-title":"Clin Auton Res"},{"key":"10.51893\/2022.4.R_bb0265","doi-asserted-by":"crossref","first-page":"e628","DOI":"10.1097\/CCM.0000000000003121","article-title":"Trends in use of midodrine in the ICU: a single-center retrospective case series","volume":"46","author":"Rizvi","year":"2018","journal-title":"Crit Care Med"},{"key":"10.51893\/2022.4.R_bb0270","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jcrc.2021.11.004","article-title":"A pilot, feasibility, randomised controlled trial of midodrine as adjunctive vasopressor for low-dose vasopressor-dependent hypotension in intensive care patients: the MAVERIC study","volume":"67","author":"Costa-Pinto","year":"2022","journal-title":"J Crit Care"},{"key":"10.51893\/2022.4.R_bb0275","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00415-008-0805-y","article-title":"Calabresi P Acute dystonia induced by the combination of midodrine and perphenazine","volume":"255","author":"Castrioto","year":"2008","journal-title":"J Neurol"},{"key":"10.51893\/2022.4.R_bb0280","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40261-015-0359-6","article-title":"Comparative clinical pharmacokinetics of midodrine and its active metabolite desglymidodrine in cirrhotic patients with tense ascites versus healthy volunteers","volume":"36","author":"Ali","year":"2016","journal-title":"Clin Drug Investig"},{"key":"10.51893\/2022.4.R_bb0285","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/ajhp\/zxy001","article-title":"Midodrine treatment in a patient with treprostinil-induced hypotension receiving hemodialysis","volume":"76","author":"Drambarean","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"10.51893\/2022.4.R_bb0290","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.chest.2016.02.657","article-title":"Feasibility, utility, and safety of midodrine during recovery phase from septic shock","volume":"149","author":"Whitson","year":"2016","journal-title":"Chest"},{"key":"10.51893\/2022.4.R_bb0295","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s13181-016-0574-4","article-title":"Severe hypertension and bradycardia secondary to midodrine overdose","volume":"13","author":"Wong","year":"2017","journal-title":"J Med Toxicol"},{"key":"10.51893\/2022.4.R_bb0300","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1046\/j.1540-8167.2001.00935.x","article-title":"Usefulness of midodrine in patients with severely symptomatic neurocardiogenic syncope: a randomized control study","volume":"12","author":"Perez-Lugones","year":"2001","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.51893\/2022.4.R_bb0305","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/sj.sc.3100959","article-title":"Midodrine hydrochloride and the treatment of orthostatic hypotension in tetraplegia: two cases and a review of the literature","volume":"38","author":"Barber","year":"2000","journal-title":"Spinal Cord"},{"key":"10.51893\/2022.4.R_bb0310","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/107424840501000109","article-title":"Successful treatment of hypotension associated with stunned myocardium with oral midodrine therapy","volume":"10","author":"Sharma","year":"2005","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.51893\/2022.4.R_bb0315","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1136\/pgmj.2003.011429","article-title":"Midodrine treatment for chronic fatigue syndrome","volume":"80","author":"Naschitz","year":"2004","journal-title":"Postgrad Med J"},{"key":"10.51893\/2022.4.R_bb0320","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.acvd.2015.11.005","article-title":"Midodrine hydrochloride and unexpected improvement in hypertrophic cardiomyopathy symptoms","volume":"109","author":"Lafitte","year":"2016","journal-title":"Arch Cardiovasc Dis"},{"key":"10.51893\/2022.4.R_bb0325","first-page":"68","article-title":"Atrial septal aneurysm with right-to-left interatrial shunting","volume":"30","author":"Chidambaram","year":"2003","journal-title":"Tex Heart Inst J"},{"key":"10.51893\/2022.4.R_bb0330","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/lt.24467","article-title":"Novel role of midodrine in pulmonary hypertension in liver transplant candidates","volume":"22","author":"Rajaram","year":"2016","journal-title":"Liver Transpl"},{"key":"10.51893\/2022.4.R_bb0335","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1378\/chest.12-3081","article-title":"Midodrine: a novel therapeutic for refractory chylothorax","volume":"144","author":"Liou","year":"2013","journal-title":"Chest"},{"key":"10.51893\/2022.4.R_bb0340","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.chest.2018.02.005","article-title":"Use of an alpha-1 adrenoreceptor agonist in the management of recurrent refractory idiopathic chylothorax","volume":"154","author":"Sivakumar","year":"2018","journal-title":"Chest"},{"key":"10.51893\/2022.4.R_bb0345","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000071122","article-title":"A pilot randomized trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke","volume":"16","author":"Hillis","year":"2003","journal-title":"Cerebrovasc Dis"},{"key":"10.51893\/2022.4.R_bb0350","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/1074248408317709","article-title":"Oral midodrine is effective for the treatment of hypotension associated with carotid artery stenting","volume":"13","author":"Sharma","year":"2008","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.51893\/2022.4.R_bb0355","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1751-7133.2008.00042.x","article-title":"The use of midodrine in patients with advanced heart failure","volume":"15","author":"Zakir","year":"2009","journal-title":"Congest Heart Fail"},{"key":"10.51893\/2022.4.R_bb0360","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/10790268.2004.11753752","article-title":"Double-blinded, placebocontrolled trial of midodrine for exercise performance enhancement in tetraplegia: a pilot study","volume":"27","author":"Nieshoff","year":"2004","journal-title":"J Spinal Cord Med"},{"key":"10.51893\/2022.4.R_bb0365","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.juro.2007.07.047","article-title":"Midodrine improves ejaculation in spinal cord injured men","volume":"178","author":"Soler","year":"2007","journal-title":"J Urol"},{"key":"10.51893\/2022.4.R_bb0370","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1111\/j.1743-6109.2008.00844.x","article-title":"Midodrine improves orgasm in spinal cord-injured men: the effects of autonomic stimulation","volume":"5","author":"Soler","year":"2008","journal-title":"J Sex Med"},{"key":"10.51893\/2022.4.R_bb0375","first-page":"70","article-title":"A preliminary report on the use of midodrine in treating refractory gastroesophageal disease: randomized double-blind controlled trial","volume":"91","author":"Bagheri Lankarani","year":"2020","journal-title":"Acta Biomed"},{"key":"10.51893\/2022.4.R_bb0380","article-title":"Blood pressure and early mobilization after total hip and knee replacements: a pilot study on the impact of midodrine hydrochloride","volume":"4","author":"Smits","year":"2019","journal-title":"JB JS Open Access"},{"key":"10.51893\/2022.4.R_bb0385","first-page":"CD001842","article-title":"Adrenergic drugs for urinary incontinence in adults","author":"Alhasso","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.51893\/2022.4.R_bb0390","first-page":"1019","article-title":"Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin","volume":"28","author":"Appenrodt","year":"2008","journal-title":"A randomized pilot study. Liver Int"},{"key":"10.51893\/2022.4.R_bb0395","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/j.1572-0241.2008.01787.x","article-title":"Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study","volume":"103","author":"Singh","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.51893\/2022.4.R_bb0400","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/MCG.0b013e31829ae376","article-title":"Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study","volume":"48","author":"Hamdy","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"10.51893\/2022.4.R_bb0405","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MEG.0000000000001277","article-title":"Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study","volume":"31","author":"Yosry","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.51893\/2022.4.R_bb0410","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jhep.2011.04.027","article-title":"Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study","volume":"56","author":"Singh","year":"2012","journal-title":"J Hepatol"},{"key":"10.51893\/2022.4.R_bb0415","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.cgh.2012.06.027","article-title":"The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis","volume":"10","author":"Bari","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.51893\/2022.4.R_bb0420","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1007\/s11606-013-2520-3","article-title":"Midodrine for orthostatic hypotension: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Parsaik","year":"2013","journal-title":"J Gen Intern Med"},{"key":"10.51893\/2022.4.R_bb0425","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1212\/WNL.0000000000000815","article-title":"Midodrine for orthostatic hypotension and recurrent reflex syncope: A systematic review","volume":"83","author":"Izcovich","year":"2014","journal-title":"Neurology"},{"key":"10.51893\/2022.4.R_bb0430","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1093\/ndt\/gfh420","article-title":"Midodrine appears to be safe and effective for dialysis-induced hypotension: a systematic review","volume":"19","author":"Prakash","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.51893\/2022.4.R_bb0435","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/MCG.0000000000000913","article-title":"Pharmacological therapies for hepatorenal syndrome: a systematic review and meta-analysis","volume":"52","author":"Nanda","year":"2018","journal-title":"J Clin Gastroenterol"},{"key":"10.51893\/2022.4.R_bb0440","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000494806","article-title":"The impact of midodrine on outcomes in patients with intradialytic hypotension","volume":"48","author":"Brunelli","year":"2018","journal-title":"Am J Nephrol"},{"key":"10.51893\/2022.4.R_bb0445","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/TP.0000000000001113","article-title":"Pretransplant midodrine use: a newly identified risk marker for complications after kidney transplantation","volume":"100","author":"Alhamad","year":"2016","journal-title":"Transplantation"},{"key":"10.51893\/2022.4.R_bb0450","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13366","article-title":"Influence of pretransplant midodrine use on outcomes after kidney transplantation","volume":"32","author":"Pottebaum","year":"2018","journal-title":"Clin Transplant"},{"key":"10.51893\/2022.4.R_bb0455","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.4254\/wjh.v8.i25.1075","article-title":"Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: a Delphi technique-based consensus","volume":"8","author":"Arab","year":"2016","journal-title":"World J Hepatol"},{"key":"10.51893\/2022.4.R_bb0460","first-page":"CD013103","article-title":"Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis","author":"Best","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.51893\/2022.4.R_bb0465","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1017\/S0265021502251352","article-title":"Midodrine, an alternative to intravenous vasopressor therapy after spinal surgery","volume":"19","author":"O'Donnell","year":"2002","journal-title":"Eur J Anaesthesiol"},{"key":"10.51893\/2022.4.R_bb0470","first-page":"e45","article-title":"The role of midodrine for hypotension outside of the intensive care unit","volume":"24","author":"Gutman","year":"2017","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"10.51893\/2022.4.R_bb0475","article-title":"Midodrine in end-stage heart failure","author":"Gonzalez-Cordero","year":"2020","journal-title":"BMJ Support Palliat Care"},{"key":"10.51893\/2022.4.R_bb0480","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12871-017-0339-x","article-title":"Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial)","volume":"17","author":"Anstey","year":"2017","journal-title":"BMC Anesthesiol"},{"key":"10.51893\/2022.4.R_bb0485","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/jcpt.12375","article-title":"Midodrine for the weaning of vasopressor infusions","volume":"41","author":"Poveromo","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"10.51893\/2022.4.R_bb0490","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13613-020-00737-w","article-title":"Potential risks in using midodrine for persistent hypotension after cardiac surgery: a comparative cohort study","volume":"10","author":"Tremblay","year":"2020","journal-title":"Ann Intensive Care"},{"key":"10.51893\/2022.4.R_bb0495","doi-asserted-by":"crossref","DOI":"10.1097\/CCE.0000000000000405","article-title":"Hemodynamic effects of an increased midodrine dosing frequency","volume":"3","author":"Macielak","year":"2021","journal-title":"Crit Care Explor"},{"key":"10.51893\/2022.4.R_bb0500","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jcrc.2013.05.021","article-title":"Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions","volume":"28","author":"Levine","year":"2013","journal-title":"J Crit Care"},{"key":"10.51893\/2022.4.R_bb0505","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1007\/s00134-020-06216-x","article-title":"Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial","volume":"46","author":"Santer","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.51893\/2022.4.R_bb0510","doi-asserted-by":"crossref","DOI":"10.1097\/CCE.0000000000000382","article-title":"Oral midodrine administration during the first 24 hours of sepsis to reduce the need of vasoactive agents: placebo-controlled feasibility clinical trial","volume":"3","author":"Lal","year":"2021","journal-title":"Crit Care Explor"},{"key":"10.51893\/2022.4.R_bb0515","doi-asserted-by":"crossref","DOI":"10.1007\/s11845-021-02903-w","article-title":"Midodrine improves clinical and economic outcomes in patients with septic shock: a randomized controlled clinical trial","author":"Adly","year":"2022","journal-title":"Ir J Med Sci"},{"key":"10.51893\/2022.4.R_bb0520","first-page":"6448504","article-title":"Effect of oral vasopressors used for liberation from intravenous vasopressors in intensive care unit patients recovering from spinal shock: a randomized controlled trial","author":"Ahmed Ali","year":"2022","journal-title":"Crit Care Res Pract"},{"key":"10.51893\/2022.4.R_bb0525","first-page":"284","article-title":"Use of oral midodrine in weaning off intravenous vasopressors in patients with septic shock","volume":"23","author":"Liu","year":"2010","journal-title":"J Pharm Pract"},{"key":"10.51893\/2022.4.R_bb0530","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/01.ccm.0000528219.66628.6d","article-title":"200: impact of oral midodrine on duration of intravenous vasopressor therapy","volume":"46","author":"Roach","year":"2018","journal-title":"Crit Care Med"},{"key":"10.51893\/2022.4.R_bb0535","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1177\/0885066619843279","article-title":"Midodrine as an adjuvant to intravenous vasopressor agents in adults with resolving shock: systematic review and meta-analysis","volume":"35","author":"Hammond","year":"2020","journal-title":"J Intensive Care Med"},{"key":"10.51893\/2022.4.R_bb0540","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/hr.2009.115","article-title":"Modulations of autonomic cardiovascular control following acute alpha-adrenergic treatment in chronic hypotension","volume":"32","author":"Duschek","year":"2009","journal-title":"Hypertens Res"},{"key":"10.51893\/2022.4.R_bb0545","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12576-008-0015-5","article-title":"Hemodynamic determinants of chronic hypotension and their modification through vasopressor application","volume":"59","author":"Duschek","year":"2009","journal-title":"J Physiol Sci"},{"key":"10.51893\/2022.4.R_bb0550","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.mehy.2010.08.010","article-title":"Alpha-2 agonists to reduce vasopressor requirements in septic shock?","volume":"75","author":"Pichot","year":"2010","journal-title":"Med Hypotheses"},{"key":"10.51893\/2022.4.R_bb0555","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1097\/CCM.0000000000003814","article-title":"Continuation of newly initiated midodrine therapy after intensive care and hospital discharge: a single-center retrospective study","volume":"47","author":"Rizvi","year":"2019","journal-title":"Crit Care Med"},{"key":"10.51893\/2022.4.R_bb0560","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.apmr.2010.06.017","article-title":"Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia","volume":"91","author":"Wecht","year":"2010","journal-title":"Arch Phys Med Rehabil"},{"key":"10.51893\/2022.4.R_bb0565","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1089\/neu.2013.3280","article-title":"Increased central arterial stiffness explains baroreflex dysfunction in spinal cord injury","volume":"31","author":"Phillips","year":"2014","journal-title":"J Neurotrauma"},{"key":"10.51893\/2022.4.R_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcrc.2022.153995","article-title":"Letter to the Editor: \"Midodrine to liberate ICU patients from intravenous vasopressors: another negative fixed-dose trial\"","volume":"69","author":"Riker","year":"2022","journal-title":"J Crit Care"},{"key":"10.51893\/2022.4.R_bb0575","article-title":"Randomised-control trials do not support midodrine as an intravenous vasopressor weaning strategy","volume":"153996","author":"Costa-Pinto","year":"2022","journal-title":"J Crit Care"},{"key":"10.51893\/2022.4.R_bb0580","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13063-022-06115-0","article-title":"LIBERATE: a study protocol for midodrine for the early liberation from vasopressor support in the intensive care unit (LIBERATE): protocol for a randomized controlled trial","volume":"23","author":"Opgenorth","year":"2022","journal-title":"Trials"},{"key":"10.51893\/2022.4.R_bb0585","doi-asserted-by":"crossref","first-page":"224A","DOI":"10.1378\/chest.1990326","article-title":"Safety of oral midodrine as a method of weaning from intravenous vasoactive medication in the medical intensive care unit","volume":"146","author":"Cardenas-Garcia","year":"2014","journal-title":"Chest"}],"container-title":["Critical Care and Resuscitation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1441277223000364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1441277223000364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T11:16:48Z","timestamp":1699269408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1441277223000364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":117,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1441277223000364"],"URL":"https:\/\/doi.org\/10.51893\/2022.4.r","relation":{},"ISSN":["1441-2772"],"issn-type":[{"value":"1441-2772","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Midodrine use in critically ill patients: a narrative review","name":"articletitle","label":"Article Title"},{"value":"Critical Care and Resuscitation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.51893\/2022.4.R","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 College of Intensive Care Medicine of Australia and New Zealand.","name":"copyright","label":"Copyright"}]}}